Asimov and RevOpsis are combining technologies to address all three dominant angiogenic pathways implicated in retinal vascular disease progression
Synthetic biology specialist Asimov has collaborated with biopharmaceutical company RevOpsis Therapeutics to develop therapies for retinal vascular diseases.
Asimov’s CHO Edge System will be integrated into Rev Opsis’ RO-104. The CHO Edge System generates stable cell lines with high titer, enabling optimisation of the expression vector and bioreactor processes across various biologics modalities.
“We are delighted that RevOpsis is joining the growing set of partners that are putting their trust in our platform,” said Asimov co-founder and CEO Alec Nielsen.
“CHO Edge will form the cornerstone of their bioproduction process for an impactful therapeutic that will serve unmet needs in a growing patient population. We look forward to supporting their biologic development as they progress through clinical trials.”
The CHO Edge System incorporates a GMP-banked CHO-K1 glutamine synthetase knockout host, or GS-Fut8 double knockout for producing afucosylated antibodies. Alongside this is a hyperactive transposase, a library of over one thousand characterised genetic parts for vector design and AI and biophysics models.
The RO-104 is designed to address all three clinically validated dominant angiogenic pathways implicated in retinal vascular disease progression (VEGF-A, VEGF-C and Ang-2), including neovascular AMD and diabetic macular edema.
“RevOpsis is committed to the rapid discovery and development of multi-specific therapies utilising our modular RevMod™ Platform that consists of fully-human libraries,” said RevOpsis co-founder and CEO Ramanath Bhandari.
“Asimov’s CHO Edge System has exhibited great performance and will underpin the development and commercialisation of our lead clinical asset RO-104 for the treatment of retinal vascular disease progression, including neovascular age-related macular degeneration.”
